8 additional undisclosed programs RD/Clin0 spinal muscular atrophy, Parkinson's, Bietti's crystalline dystrophy, hemophilia A, phenylketonuria
Exegenesis Bio is a multinational company advancing innovative gene and cell therapies focused on three initial areas: central nervous system (CNS), ophthalmology and liver. To advance therapies in these areas, Exegenesis is using their proprietary discovery and manufacturing platforms including AAVarta®, an in-silico evolution discovery platform to design novel AAV capsids using AI technologies. Other platforms include Constellation®, an AI aided gene expression cassette design platform and Progress®, a data-driven protein engineering platform. Together, Exegenesis is advancing a diverse pipeline with lead programs for Spinal Muscular Atrophy and Age-Related Macular Degeneration in early stage clinical trials.